ANN ARBOR, Mich. & PHILADELPHIA--()--SensiGen LLC, a biotechnology company developing proprietary gene-based molecular diagnostics announced today the closing of a $300,000 investment from Delaware Crossing Investor Group, a Mid-Atlantic region angel investor group. The funds will be used to help SensiGen accelerate development and commercialization of the Company’s revolutionary AttoSense™ molecular diagnostic technology.
“We look forward to working with the SensiGen team in the months and years ahead.”
“We are very excited to have Delaware Crossing as an investor,” said Shawn M. Marcell, President and CEO of SensiGen. “They are a unique type of investment group with access to a broad array of expertise and resources valuable to emerging growth companies like SensiGen.”
SensiGen has developed a breakthrough molecular diagnostic technology based on the coupling of Polymerase Chain Reaction (PCR) technology with Mass Spectrometry (MS) to achieve unprecedented levels of sensitivity and specificity in pinpointing the biomarkers that signal the onset of major disease or the pathogens that cause them. To date, the Company has raised nearly $3.5 million in investments from the Michigan Economic Development Corporation, the management team, and a variety of angel investors in addition to the investment from Delaware Crossing.
“SensiGen has incredible technology and a solid, experienced management team, and is now well positioned for rapid growth as they commercialize several exciting new medical diagnostics that will save lives and improve health care for millions of people,” said Mohan Philip, a Delaware Crossing member who focuses on Life Sciences ventures. “We look forward to working with the SensiGen team in the months and years ahead.”
About SensiGen, LLC: SensiGen is a biotechnology company focused on gene-based molecular diagnostics. The Company develops advanced technologies to enable early detection of diseases, thereby improving the standard of care and reducing overall health costs. Current products in development include tests for early detection of human papillomavirus (HPV)—the primary cause of cervical cancer—chronic kidney disease (CKD), Crohn’s disease, Lupus and others. SensiGen’s proprietary molecular diagnostic assays offer dramatic improvements over current methods. www.sensigen.com
About Delaware Crossing Investor Group: The Delaware Crossing Investor Group is an angel group located in Bucks County, PA that invests in early-stage companies located in the Philadelphia and Princeton region. Delaware Crossing was formed in 2005 and has made 10 investments. Delaware Crossing seeks high-growth businesses with high investment return potential. www.delawarecrossing.org
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
